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Summary
 
We have previously reported (Badolato, R., J.M. Wang, W.J. Murphy, A.R. Lloyd, D.F.
Michiel, L.L. Bausserman, D.J. Kelvin, and J.J. Oppenheim. 1994. 
 
J. Exp. Med.
 
 180:203; Xu,
L., R. Badolato, W.J. Murphy, D.L. Longo, M. Anver, S. Hale, J.J. Oppenheim, and J.M.
Wang. 1995. 
 
J. Immunol.
 
 155:1184.) that the acute phase protein serum amyloid A (SAA) is a
potent chemoattractant for human leukocytes in vitro and mouse phagocytes in vivo. To iden-
tify the signaling mechanisms, we evaluated patterns of cross-desensitization between SAA and
other leukocyte chemoattrctants. We found that the chemotactic bacterial peptide, 
 
N
 
-formyl-
methionyl-leucyl-phenylalanine (fMLP), was able to specifically attenuate Ca
 
2
 
1
 
 mobilization in
human phagocytes induced by SAA, but only at very high concentrations, suggesting that SAA
uses a low affinity fMLP receptor. Here we demonstrate that SAA selectively induced Ca
 
2
 
1
 
mobilization and migration of HEK cells expressing FPRL1, a human seven-transmembrane
domain phagocyte receptor with low affinity for fMLP, and high affinity for lipoxin A4. Fur-
thermore, radiolabeled SAA specifically bound to human phagocytes and FPRL1-transfected
293 cells. In contrast, SAA was not a ligand or agonist for FPR, the high affinity fMLP recep-
tor. Thus, SAA is the first chemotactic ligand identified for FPRL1. Our results suggest that
FPRL1 mediates phagocyte migration in response to SAA.
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S
 
erum amyloid A (SAA),
 
1
 
 an acute phase protein, is nor-
mally present in serum at 0.1-
 
m
 
M levels, but increases
by 1,000-fold in systemic inflammatory conditions (1–4). It
has been proposed that SAA is mainly involved in lipid
transportation and metabolism (1–3). Chronic inflamma-
tory conditions with elevated serum SAA may culminate in
amyloidosis, characterized by deposition of “amyloid”
fibrils in tissues and associated with progressive destruction
of organ function (2–4). Although a number of acute phase
proteins are known to modulate host immune responses,
we recently reported that recombinant human (rh)SAA ex-
hibited considerable chemoattractant activity for human
monocytes, neutrophils, and T lymphocytes in vitro (5, 6).
rhSAA also induced infiltration of phagocytic cells and T
lymphocytes into injection sites in mice (5, 6), suggesting
that SAA, when present locally, may play a proinflamma-
tory role by recruiting immune cells.
 
Since SAA induced significant Ca
 
2
 
1
 
 mobilization in phago-
cytes (7), and both its chemotactic and Ca
 
2
 
1
 
 mobilizing ef-
fects were inhibitable by pretreatment of the leukocytes with
pertussis toxin, we proposed that SAA may use seven-trans-
membrane, G protein–coupled receptor(s) (6, 7). In an effort
to identify the receptor(s) for SAA, we carefully evaluated
cross-desensitization of Ca
 
2
 
1
 
 mobilization in monocytes and
neutrophils induced by SAA and other chemoattractants.
Among a number of chemoatrractants tested, only the bacte-
rial chemotactic peptide 
 
N
 
-formyl-methionyl-leucyl-phenyl-
alanine (fMLP), when used at relatively high concentrations
 
(10 
 
m
 
M and more), was able to attenuate a subsequent cell
response to SAA, suggesting that SAA may use a receptor on
leukocytes for which fMLP has low affinity.
Two receptors that interact with fMLP have been iden-
tified and molecularly cloned (for review see references 8,
9). The prototype receptor FPR bound fMLP with high
 
1
 
Abbreviations used in this paper:
 
 CI, chemotaxis indexes; EC, effective con-
centration; fMLP, 
 
N
 
-formyl-methionyl-leucyl-phenylalanine; HDL, high
density lipoprotein; LXA4, lipoxin A4; SAA, serum amyloid A. 
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affinity and was activated by low nanomolar concentrations
of fMLP. The other, a highly homologous variant of FPR,
named FPRL1 (also referred to as FPRH2 and LXA4R),
was originally cloned as an orphan receptor (10–14) but
was subsequently found to mediate Ca
 
2
 
1
 
 mobilization in
response to high concentrations of fMLP (11, 13). Further-
more, a lipid metabolite, lipoxin A4 (LXA4), and its ana-
logues were subsequently found to bind FPRL1 with high
affinity and to increase arachidonic acid production and G
protein activation in FPRL1-transfected cells (15). LXA4
inhibits proinflammatory neutrophil responses (15–23) as
well as the release of the proinflammatory cytokine, IL-8,
by epithelial cells (20, 24). These effects of LXA4 have
been attributed to the activation of FPRL1 (or LXA4R) in
neutrophils and epithelial cells. Another lipid mediator re-
ceptor, the leukotriene B4 receptor, is structurally related
to FPRL1 (30.7% amino acid sequence identity; reference
25), and was also reported to be a fusion co-factor for HIV-1
(26), similar to various chemokine receptors (for review
see reference 27). This activity has not been reported for
FPRL1 (9, 27). Because SAA might use a low affinity
fMLP receptor on phagocytes, we further investigated
whether FPRL1 could be activated by SAA and demon-
strate that SAA uses FPRL1 as a functional receptor.
 
Materials and Methods
 
Reagents and Cells.
 
rhSAA was purchased from Pepro Tech
Inc. with the sequence as follows: MRSFFSFLGEAFDGARD-
MWRAYSDMREANYIGSDKYFHARGNYDAAKRGPGGV-
WAAEAISNARENIQRFFGRGAEDSLADQAANEWGRSGK-
DPNHFRPAGLPEKY.
This rhSAA corresponds to SAA-1
 
a
 
, one of the major SAA
isoforms in the serum, except for the addition of a methionine at
the NH
 
2
 
 terminus as well as the substitution of aspartic acid for
asparagine at position 60, which appears in the SAA2 isoform (for
review see reference 28). rhSAA at concentrations used in the
study was negative for endotoxin as assessed by Limulus amebo-
cyte lysate assays (sensitivity: 0.06 IU/ml; BioWhittaker). High
density lipoprotein (HDL) was purchased from Sigma Chemical
Co. Human peripheral blood enriched in mononuclear cells or
neutrophils was obtained from normal donors by leukapheresis
(courtesy of the Transfusion Medicine Department, Clinical
Center, National Institutes of Health, Bethesda, MD). The blood
was centrifuged through Ficoll-Hypaque (Sigma Chemical Co.),
and PBMCs collected at the interphase were washed with PBS
and centrifuged through a 46% isoosmotic Percoll (Pharmacia,
Uppsala, Sweden) gradient followed by elutriation to yield
monocytes (purity: 
 
.
 
90%). Neutrophils were purified by 3%
dextran/PBS sedimentation as described elsewhere (5) and were
 
.
 
98% pure. The cells were resuspended in RPMI 1640 medium
containing 10% FCS (Hyclone) for future use. The molecular
cloning of the receptors for fMLP has been described previously
(10, 13, 29, 30). The cDNAs encoding classical formyl peptide
receptor FPR and its variant FPRL1 were stably transfected into
human embryonic kidney epithelial cell line 293, which was cul-
tured in DMEM in the presence of 800 
 
m
 
g/ml geneticin (G418;
GIBCO BRL) to maintain selection. A rat basophil leukemia cell
line stably transfected with FPR (ETFR cells) was also used in
the study (gift from Drs. H. Ali and R. Snyderman, Duke Uni-
versity Medical Center, Durham, NC).
 
Chemotaxis.
 
The migration of human 293 cells expressing
FPR (FPR/293) or FPRL1(FPRL1/293) as well as ETFR cells
was assessed by a 48-well microchemotaxis chamber technique
(31, 32). A 25-
 
m
 
l aliquot of rhSAA or other reagents diluted in
chemotaxis medium (RPMI 1640, 1% BSA, 25 mM Hepes) was
placed in the wells of the lower compartment, and 50 
 
m
 
l cell sus-
pension (10
 
6 
 
cell/ml in chemotaxis medium) were placed in the
wells of the upper compartment of the chamber (Neuroprobe,
Cabin John, MD). The two compartments were separated by a
polycarbonate filter (10 
 
m
 
m pore size, Neuroprobe) coated with
50 
 
m
 
g/ml collagen type I (GIBCO BRL) for 1 h at 37
 
8
 
C. The
chamber was incubated at 37
 
8
 
C for 5 h in humidified air with 5%
CO
 
2
 
. At the end of the incubation, the filter was removed, fixed
and stained with Diff-Quik (Harlew, Gibbstown, NJ). The num-
ber of migrated cells in three high-powered fields (400
 
3
 
) was
counted by light microscopy after coding the samples. Results are
expressed as the mean (
 
6
 
 SD) value of the migration in triplicate
samples and are representative of at least five experiments per-
formed. For better illustration, chemotaxis indices (CI) reflecting
the fold increase of cell migration in response to stimulant over
medium are used. Statistical significance of the difference be-
tween numbers of cells migrating in response to stimuli versus
baseline (migration toward control medium) was calculated with
Student’s 
 
t
 
 test and the CI 
 
$ 
 
2 are statistically significant.
 
Calcium Mobilization.
 
Calcium mobilization was assayed by
incubating 10
 
7
 
/ml of monocytes, neutrophils, or receptor cDNA
transfectants in loading buffer containing 138 mM NaCl, 6 mM
KCl, 1 mM CaCl
 
2
 
, 10 mM Hepes (pH 7.4), 5 mM glucose, and
0.1% BSA with 5 
 
m
 
M Fura-2 (Sigma Chemical Co.) at 37
 
8
 
C for
30 min. The dye-loaded cells were washed and resuspended in
fresh loading buffer. The cells were then transfered into quartz
cuvettes (10
 
6
 
 cells in 2 ml) that were placed in a luminescence
spectrometer LS50 B (Perkin-Elmer Limited). Stimulants at dif-
ferent concentrations were added in a volume of 20 
 
m
 
l to the cu-
vettes at indicated time points. The ratio of fluorescence at 340
and 380 nm wavelengths was calculated using the FL WinLab
(Perkin Elmer) program. The assays were performed at least five
times and results from representative experiments are shown.
 
Ligand Binding Assays.
 
rhSAA (20 
 
m
 
g) was radio-iodinated on
tyrosine residues with the chloramine T method and the specific ac-
tivity of the labeled SAA was 5.8 mCi/mg (courtesy of J. Dobbs,
SAIC Frederick, NCI-FCRDC, Frederick, MD). A constant con-
centration of 16 nM 
 
125
 
I-labeled SAA was incubated for 20 min at
37
 
8
 
C with human monocytes or 293 cells transfected with
chemoattractant receptor cDNAs (1.5–2 
 
3 
 
10
 
6
 
/sample, in 200 
 
m
 
l
RPMI 1640, 1% BSA, 0.05% NaN3) in the presence of increasing
concentrations of unlabeled SAA. After incubation, the cells were
washed once with ice-cold PBS then were layered onto a 10% su-
crose/PBS cushion in Eppendorf tubes. The cells were centrifuged
at 10,000 
 
g
 
 for 1 min and the tips of the tubes containing cell pellets
were cut and measured for radioactivity in a gamma counter. The
binding data were analyzed and plotted with a computer-aided pro-
gram LIGAND (P. Munson, Division of Computer Research and
Technology, NIH, Bethesda, MD). The level of specific binding
was determined by subtraction of nonspecific binding (cpm on cells
in the presence of 1 
 
m
 
M unlabeled SAA) from the total binding
(cpm on cells in the absence of unlabeled SAA). Experiments were
performed at least five times, yielding similar results each time.
 
Results
 
Assays of Ca
 
2
 
1
 
 mobilization have provided a useful ap-
proach to identify ligands for chemoattractant receptors. In 
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29), we tested the effect of SAA using cells transfected to
express these receptors that originally were not responsive
to fMLP stimulation. fMLP in a wide range of concentra-
tions induced Ca
 
2
 
1
 
 
 
mobilization in FPR-transfected rat ba-
sophil leukemia cell line (ETFR cells), with an EC
 
50
 
 of 10
pM (data not shown). In contrast, the EC
 
50
 
 for fMLP
to induce Ca
 
2
 
1
 
 
 
mobilization in FPRL1 transfected cells
(FPRL1/293 cells) was much higher at 10 
 
m
 
M (Fig. 2 A).
These results confirmed the previous observation that FPR
is a high affinity receptor for fMLP, whereas FPRL1 has a
much lower affinity (10, 11, 13, 29). rhSAA induced Ca
 
2
 
1
 
mobilization in cells transfected with FPRL1 (FPRL1/293
cells; Fig. 2 B), but not in FPR-expressing cells or mock-
transfected 293 cells (Fig. 2, C and D). The EC
 
50 
 
of rhSAA
on FPRL1 transfected cells was 250 nM, suggesting that SAA
activates FPRL1 with higher efficacy than fMLP. This was
supported by studies of cross-desensitization of Ca
 
2
 
1
 
 
 
flux be-
tween SAA and fMLP in FPRL1/293 cells. As shown in Fig.
2 E, although sequential stimulation of FPRL1/293 cells with
SAA and fMLP resulted in bidirectional desensitization, SAA
was able to desensitize the cell response to a 100-fold excess
of fMLP. In contrast, fMLP at 100-fold excess of SAA only
partially desensitized the effect of SAA (Fig. 2 E).
Leukocyte infiltration in vivo is considered to be based
on migration of cells toward a gradient of locally produced
chemoattractant(s). This process can be emulated by in
vitro assays of chemotaxis, which provides a very sensitive
and biologically relevant means of evaluating the function
of cloned chemoattractant receptors (32–35). Since SAA
has been shown in our previous studies to induce leukocyte
infiltration in vivo and chemotaxis in vitro (5, 6), we next
investigated whether SAA could induce cell migration via
FPRL1. FPRL1/293 cells showed a potent migratory re-
sponse to SAA with an EC
 
50
 
 of 200 nM (Fig. 3 A), but
these cells failed to migrate in response to a wide range of
concentrations of fMLP (Fig. 3 B). In contrast, fMLP in-
duced migration of ETFR cells at nanomolar range con-
centrations, whereas the same cells did not migrate in re-
sponse to SAA (Fig. 3 C). The chemotaxis experiments
indicate that fMLP is only a partial agonist for FPRL1 since
it did not induce cell migration through FPRL1. On the
other hand, SAA showed full agonist activity on FPRL1.
Both SAA-induced Ca
 
2
 
1
 
 mobilization and chemotaxis in
FPRL1/293 cells were inhibited by pretreatment of the
cells with pertussis toxin but not cholera toxin (data not
shown) in correlation with the observation in native cells
(5–7), suggesting activation of G protein of the Gi type is
required for SAA signaling through FPRL1. In addition,
since SAA can form complexes with HDL, which acts as a
natural inhibitor of SAA (5, 6), we examined the effect of
HDL on the chemotactic activity of SAA for FPRL1/293
cells. Fig. 3 D shows that HDL, whether preincubated with
SAA or simultaneously added to SAA, completely abol-
ished SAA-induced FPRL1/293 cell migration. In contrast,
the same concentration of HDL did not affect migration of
FPR-expressing ETFR cells induced by fMLP (data not
shown). These results confirmed that HDL specifically in-
hibited the agonist activity of SAA on FPRL1.
Figure 1. Cross-desensitization of Ca21 mobilization in human mono-
cytes between SAA and fMLP. Fura-2–loaded monocytes were sequen-
tially stimulated with SAA and fMLP (A) or vice versa (B and C), and the
ratio of fluorescence at 340 and 380 nm wavelengths was recorded and
calculated with the FLWinLab program.
 
primary cells, cross-desensitization of Ca
 
2
 
1
 
 transients is of-
ten due to two agonists acting at the same receptor (33).
Since SAA induced Ca
 
2
 
1
 
 mobilization in phagocytes (7),
we used cross-desensitization to characterize the molecular
nature of SAA receptor(s). In a series of cross-desensitiza-
tion experiments, SAA at 1 
 
m
 
M did not desensitize the
Ca
 
2
 
1
 
 flux in monocytes or neutrophils induced by chemo-
kines such as monocyte chemotactic protein (MCP)-1,
RANTES, MCP-3, macrophage inflammatory protein
(MIP)-1
 
a
 
, IL-8, and stromal cell–derived factor (SDF)-1
 
a
 
(data not shown). Therefore, SAA is unlikely to share a re-
ceptor with any of the chemokines tested. SAA also did not
attenuate the cell response to the bacterial chemotactic
N-formylated peptide fMLP when fMLP was used at 100 nM
(10
 
2
 
7
 
 M) (Fig. 1 A). However, in reciprocal tests, fMLP
at 100 nM showed a partial desensitizing effect on SAA-
induced Ca
 
2
 
1
 
 
 
mobilization in monocytes (Fig. 1 B). Further-
more, the cell response to SAA was completely desensitized
by higher concentrations of fMLP (10
 
2
 
3 
 
M 
 
5 
 
1 mM, Fig. 1
C), suggesting that SAA might use a receptor(s) for which
fMLP has low affinity.
Since fMLP is known to induce Ca
 
2
 
1
 
 mobilization in
phagocytes through at least two seven-transmembrane, G
protein–coupled receptors, FPR and FPRL1 (10, 11, 13, 
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To further verify the usage of FPRL1 by SAA, we per-
formed ligand binding experiments. Fig. 4 shows that ra-
dio-iodinated SAA specifically bound to FPRL1/293 cells
with an estimated 
 
K
 
d
 
 at 64 nM and 42,000 binding sites per
cell (Fig. 4 A). 
 
125
 
I-labeled SAA also specifically bound to
monocytes (Fig. 4 B) and neutrophils (
 
K
 
d
 
 
 
5 
 
45 nM, 
 
R
 
 
 
5
 
6,700/cell) with 
 
K
 
d
 
 values comparable to those achieved
with FPRL1/293 cells. In the displacement assay, unla-
beled SAA in a dose-dependent manner inhibited its own
binding to monocytes (Fig. 4 C), neutrophils (data not
shown) and FPRL1/293 (Fig. 4 D) with an IC
 
50
 
 at 
 
z
 
50
nM. In contrast, unlabeled fMLP at high concentrations
(
 
$
 
10 
 
m
 
M) only partially competed with 
 
125
 
I-SAA for bind-
ing. These results confirm SAA to be a far more efficient
agonist for FPRL1 than fMLP.
 
Discussion
 
In this study, we demonstrate that SAA uses FPRL1, a
seven-transmembrane, G protein–coupled receptor ex-
pressed on phagocytes as a chemotactic receptor, suggesting
a molecular basis for our previous observations that SAA is
a potent chemoattractant and activator for human periph-
eral blood monocytes and neutrophils (5–7). In addition to
SAA, FPRL1 has previously been shown to be a low affin-
ity receptor for fMLP (11, 13) and a high affinity receptor
for lipid metabolite LXA4 and its analogues (15–24). Our
data suggest that fMLP is a partial agonist incapable of in-
ducing chemotaxis via FPRL1 in this model system. Analy-
sis of LXA4 induction of chemotaxis via FPRL1 has not
been reported. Thus, SAA is the first chemotactic agonist
identified for FPRL1.
FPRL1 was identified and molecularly cloned from hu-
man phagocytic cells by low stringency hybridization of the
cDNA library with the FPR sequence and initially was de-
fined as an orphan receptor (10, 11, 13, 14). The cloning of
the same receptor termed FPRH2 from a genomic library
was described by Bao et al. (12). FPRL1 possesses 69%
identity at the amino acid level to FPR, the prototype re-
ceptor for synthetic and bacterium-derived formylated
peptides (8, 9). Both FPR and FPRL1 are expressed by
monocytes and neutrophils and are clustered on human
chromosome 19q13 (12, 36). Although fMLP is a high af-
finity agonist for FPR, it interacts with FPRL1 and trans-
duces signals in response to fMLP only at high concentra-
tions (Fig. 2 and references 11, 13, 36). SAA, on the other
hand, selectively bound and activated only FPRL1 at phys-
iologically relevant concentrations, which under inflamma-
tory stimulation could reach 80 
 
m
 
M in the serum (1–4).
FPRL1 is mainly expressed in monocytes and neutrophils.
However, cells other than phagocytes, such as hepatocytes,
have also been shown to express FPRL1 (8). Recently, the
expression of this receptor (also termed LXA4R) has been
reported to be highly inducible in epithelial cells by specific
cytokines (20). Our previous study showed that CD3
 
1
 
 hu-
man peripheral blood T lymphocytes were induced by
SAA to migrate and adhere to endothelial cell monolayers
(6), suggesting that T lymphocytes may also express a re-
ceptor(s) for SAA. In fact, we detected specific binding sites
for 
 
125
 
I-labeled SAA on human peripheral blood CD31 T
lymphocytes (Kd 5 300 nM, R 5 2,200 sites/cell). How-
ever, whether these binding sites on T lymphocytes repre-
sent FPRL1 or an additional receptor(s) for SAA is not yet
known.
Despite the fact that the chemotactic formyl peptide
fMLP has been shown to be a low efficiency agonist for
FPRL1, a lipid metabolite LXA4 has been reported to be a
high affinity ligand and potent agonist for this receptor
Figure 2. Calcium mobilization in
FPRL1-transfected HEK 293 cells.
FPRL1/293 cells were loaded with
Fura-2 and were stimulated with various
concentrations of fMLP (A) or SAA (B).
SAA does not induce Ca21 mobilization
in FPR-expressing 293 cells (C) or
mock-transfected 293 cells (D). E shows
the sequential stimulation of FPRL1/293
cells with SAA and fMLP or vice versa.399 Su et al.
(15). LXA4 is an eicosanoid generated during a number of
host reactions such as inflammation, thrombosis, and ath-
erosclerosis (22), and was initially discovered as an inhibitor
of immune response (for review see reference 37). LXA4
was subsequently reported to inhibit neutrophil chemotaxis
(38) and transepithelial migration induced by chemotactic
agents (23). A seven-transmembrane, G protein–coupled
receptor identical to FPRL1 was recently identified for
LXA4 (15, 16, 22). LXA4 bound to CHO cells transfected
with this receptor with high affinity and increased GTPase
activity and the release of esterified arachidonate (15).
Thus, LXA4 has been proposed to be an endogenously
Figure 3. Chemotactic activity of SAA for human monocytes and cells transfected to express chemoattractant receptors. Different concentrations of SAA
were placed in the lower wells of the chemotaxis chamber. Monocytes, FPRL1/293 cells, or FPR-expressing ETFR cells were placed in the upper wells. Af-
ter incubation, the cells migrated across the polycarbonate filter were counted and photographed (A: SAA 0.8 mM, fMLP 100 nM). The cell migration was
expressed as CI representing the fold increase of the cells migrating in response to stimulants over control medium. (B) Migration of FPRL1/293 cells in
response to SAA and fMLP. (C) Migration of FPR-expressing ETFR cells in response to SAA and fMLP. (D) Effect of HDL on SAA induced FPRL1/293
cell migration. HDL at 1,000 mg/ml mixed with 0.8 mM SAA was preincubated at 378C for 4 h. The mixture was then tested for chemotactic activity on
FPRL1/293 cells. The HDL/SAA mixture without preincubation was also tested for chemotactic activity and yielded similar results.400 Activation of a Chemoattractant Receptor FPRL1 by SAA
produced ligand for FPRL1 (15, 16). Although LXA4 has
not been documented to induce Ca21 mobilization in neu-
trophils or FPRL1-transfected cells (15), it was reported to
induce Ca21 flux and chemotaxis in monocytes, presum-
ably through FPRL1 (17, 22). Thus, differential activation
of second messengers in monocytes versus neutrophils by
LXA4 was postulated. In our study, we did not detect sig-
nificant induction of Ca21 flux or chemotaxis in FPRL1/
293 cells by a commercially available LXA4 (Biomol, Ply-
mouth Meeting, PA), nor did we observe inhibition of
SAA signaling or binding by this LXA4 in either phago-
cytes or FPRL1/293 cells. Further study, beyond the scope
of this report, will be needed to compare the interaction of
FPRL1 with its peptide ligands, SAA and fMLP, versus its
lipid ligand, LXA4, to clarify these results.
Our previous studies showed that both SAA-induced
leukocyte chemotaxis and activation were inhibited by per-
tussis toxin (6, 7). This study also showed that the signaling
of SAA through FPRL1 was sensitive to pertussis toxin.
Thus, although the signal transduction pathways triggered
by SAA in FPRL1 requires further investigation, the high
level homology of FPRL1 to FPR, its sensitivity to pertus-
sis toxin, and its mediation of potent phagocyte activation
by SAA suggest that FPRL1 may share major biochemical
events with FPR. It is well known that binding of FPR by
bacterium-derived or synthetic peptide agonists results in a
G protein–mediated signaling cascade leading to phagocytic
cell adhesion, chemotaxis, release of oxygen intermediates,
enhanced phagocytosis, and bacterial killing, as well as gene
transcription (8, 9). Activation of FPR by its agonists can also
result in heterologous desensitization of the subsequent cell
response to other G protein receptor ligands (39, 40), includ-
ing chemokines. This “desensitizing” effect of FPR activa-
tion may also be seen with FPRL1, although more studies
are needed to elucidate the mechanism(s) involved. For in-
stance, SAA was initially reported as an inhibitor of neutro-
phil response to fMLP (41). In these experiments, neutro-
phils preincubated with SAA showed reduced superoxide
release in response to fMLP (41). Our previous study also
showed that preincubation of monocytes and neutrophils
with SAA reduced cell response to a number of chemo-
attractants, including fMLP and chemokines (7), suggesting
that FPRL1 is capable of transducing intracellular bio-
chemical events leading to desensitization of other G pro-
tein–coupled receptors.
The pathophysiological significance of use of FPRL1 by
SAA requires more in-depth investigation. The optimal
concentrations for SAA to induce leukocyte migration, ad-
hesion, and tissue infiltration ranged from 0.8 to 4 mM (5–
7), which are higher than the SAA levels present in normal
serum but well below the concentration seen during a sys-
temic acute phase response (1–4). Increased serum levels of
SAA have been observed in a number of inflammatory and
infectious diseases as well as after organ transplantation (4).
Figure 4. Binding of
125I-labeled SAA to human
monocytes and FPRL1/293 cells.
rhSAA was radio-iodinated with
chloramine T method and the
binding of 125I-labeled SAA to
FPRL1/293 cells (A) or mono-
cytes (B) was measured by add-
ing a constant concentration of
125I-labeled SAA to the cells in
the presence of increasing con-
centrations of unlabeled SAA.
The data was analyzed and plot-
ted with the Macintosh computer
aided program LIGAND. C
shows the displacement of
125I-labeled SAA binding on
monocytes by unlabeled SAA and
fMLP. The same results were ob-
tained with neutrophils (data not
shown) and FPLR1/293 cells (D).401 Su et al.
The SAA concentrations required for activating FPRL1 are
well within the range in which native cells are activated, as
shown in this study. The overproduction of SAA by hepa-
tocytes can be induced by inflammatory stimuli such as
LPS, IL-1, IL-6, and TNF-a (1–4). Macrophages have also
been reported as an extra-hepatic source of SAA during in-
flammation (42) and may produce relatively high concen-
trations in microcompartments. The expression of SAA
mRNA in human atherosclerotic lesions and the induction
of SAA by oxidized low density lipoproteins strengthen the
hypothesis that SAA may play an important role in vascular
injury and atherosclerosis (4). Under normal conditions,
most serum SAA will be associated with HDL, which acts
as a natural inhibitor of the chemotactic activity of SAA
(references 5, 6 and Fig. 3 D). However, since SAA binds
to HDL at equimolar ratios (43), a rapid increase in con-
centration of locally produced SAA could establish a gradi-
ent of free active SAA with consequent recruitment of leu-
kocytes into inflammatory sites. Therefore, it is possible
that at local inflammatory sites elevated SAA can attract and
activate leukocytes for the clearance of pathogenic agents.
This process may also cause tissue injury. Furthermore, sig-
nals triggered by activated FPRL1, a functional receptor of
SAA, could eventually result in unresponsiveness of leuko-
cytes to additional stimulation, thus immobilizing the cells
and limiting the degree of inflammation.
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